MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

Search

CRISPR Therapeutics AG

Closed

SectorHealthcare

68.29 -6.46

Overview

Share price change

24h

Current

Min

67.87

Max

75.02

Key metrics

By Trading Economics

Income

-73M

-209M

Sales

27K

892K

Profit margin

-23,379.933

Employees

393

EBITDA

-59M

-203M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

-5.38% downside

Dividends

By Dow Jones

Next Earnings

4 lis 2025

Market Stats

By TradingEconomics

Market Cap

1.2B

6.4B

Previous open

74.75

Previous close

68.29

News Sentiment

By Acuity

64%

36%

329 / 371 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

CRISPR Therapeutics AG Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

12 paź 2025, 21:50 UTC

Acquisitions, Mergers, Takeovers

Caterpillar to Acquire Australia's RPM Global for $730 Million

10 paź 2025, 21:38 UTC

Acquisitions, Mergers, Takeovers

Strathcona Resources Terminates Take-Over Bid for MEG Energy

12 paź 2025, 23:47 UTC

Market Talk

Gold Rises, Buoyed by Monetary Debasement Fears -- Market Talk

12 paź 2025, 23:39 UTC

Market Talk

Oil Rises on Likely Technical Recovery, Mildly Positive Sentiment -- Market Talk

12 paź 2025, 23:22 UTC

Market Talk

New Zealand Braces For Renewed Trade War Uncertainty -- Market Talk

12 paź 2025, 23:16 UTC

Acquisitions, Mergers, Takeovers

Caterpillar Inc. Enters Into Agreement To Acquire RPMGlobal >CAT RUL.AU

12 paź 2025, 22:32 UTC

Market Talk

Copper, U.S. Thermal Coal Stand Out as Metals Ride Macro Tailwinds -- Market Talk

12 paź 2025, 21:28 UTC

Acquisitions, Mergers, Takeovers

RPM Global Says Board Unanimously Recommends Shareholders Accept Caterpillar Offer

12 paź 2025, 21:28 UTC

Acquisitions, Mergers, Takeovers

RPM Global Agrees to Takeover by Caterpillar

12 paź 2025, 21:28 UTC

Acquisitions, Mergers, Takeovers

RPM Global Says Caterpillar Offering A$5.00/Share in Cash

11 paź 2025, 08:20 UTC

Market Talk

Financial Services Roundup: Market Talk

11 paź 2025, 00:18 UTC

Acquisitions, Mergers, Takeovers

Why Biotech May Be Back -- Barrons.com

10 paź 2025, 21:07 UTC

Earnings
Acquisitions, Mergers, Takeovers

Dell Is Just Beginning to Tell Its AI Story. Buy the Stock. -- Barrons.com

10 paź 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

10 paź 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

10 paź 2025, 20:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

10 paź 2025, 20:06 UTC

Market Talk

Fed Won't Publish Monthly Industrial Data Next Week -- Market Talk

10 paź 2025, 20:06 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

10 paź 2025, 19:56 UTC

Market Talk

U.S.-China Tension Weighs Down on Treasury Yields, Dollar -- Market Talk

10 paź 2025, 19:20 UTC

Market Talk

Oil Futures Sink As Trump Rekindles Trade Tensions -- Market Talk

10 paź 2025, 19:02 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Loss -- Market Talk

10 paź 2025, 18:58 UTC

Market Talk

Canada's Jobs Gain Marks a 'Head Fake' For Economy -- Market Talk

10 paź 2025, 18:52 UTC

Market Talk

PepsiCo Lays Groundwork for Improvement -- Market Talk

10 paź 2025, 18:47 UTC

Market Talk

Precious Metals Turn Higher After Profit-Taking Slide -- Market Talk

10 paź 2025, 18:35 UTC

Market Talk

Canada's Next Rate Cut May be Pushed to December -- Market Talk

10 paź 2025, 18:31 UTC

Market Talk

Canada's Labor Market Firming. But Conditions Vary Across Country -- Market Talk

10 paź 2025, 17:32 UTC

Market Talk

U.S. Oil Rig Count Declines by Four to 418 -- Market Talk

10 paź 2025, 16:55 UTC

Earnings

These Stocks Are Moving the Most Today: MP Materials, Nvidia, Alibaba, Venture Global, Applied Digital, Qualcomm, and More -- Barrons.com

10 paź 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

10 paź 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

Peer Comparison

Price change

CRISPR Therapeutics AG Forecast

Price Target

By TipRanks

-5.38% downside

12 Months Forecast

Average 69.14 USD  -5.38%

High 99 USD

Low 40 USD

Based on 17 Wall Street analysts offering 12 month price targets forCRISPR Therapeutics AG - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

17 ratings

11

Buy

6

Hold

0

Sell

Technical Score

By Trading Central

33.5 / 38.27Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

329 / 371 Ranking in Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
help-icon Live chat